Evidence map›Paper›PMID 28535157›Full record

SynthesisBritish journal of cancer2017

A meta-analysis of CXCL12 expression for cancer prognosis.

Harsh Samarendra, Keaton Jones, Tatjana Petrinic, Michael A Silva, Srikanth Reddy, Zahir Soonawalla, Alex Gordon-Weeks

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Clinical Medicine Insights. Oncology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. The role of the CXCL12/CXCR4 axis in the immunotherapy of non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  15. Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Harsh SamarendraMedical Sciences Division, University of Oxford, Oxford, UK.
Keaton JonesCRUK/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK.
Tatjana PetrinicCairns Library, John Radcliffe Hospital, Oxford, UK.
Michael A SilvaDepartment of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS Trust, Oxford, UK.
Srikanth ReddyDepartment of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS Trust, Oxford, UK.
Zahir SoonawallaDepartment of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS Trust, Oxford, UK.
Alex Gordon-WeeksNuffield Department of Surgical Sciences, University of Oxford, Room 6607, Level 6, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK.
Oxford University Hospitals NHS Trust · GBJohn Radcliffe Hospital · GBCRUK/MRC Oxford Institute for Radiation Oncology · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCXCL12 (SDF1) is reported to promote cancer progression in several preclinical models and this is corroborated by the analysis of human tissue specimens. However, the relationship between CXCL12 expression and cancer survival has not been systematically assessed.

methodsWe conducted a systematic review and meta-analysis of studies that evaluated the association between CXCL12 expression and cancer survival.

resultsThirty-eight studies inclusive of 5807 patients were included in the analysis of overall, recurrence-free or cancer-specific survival, the majority of which were retrospective. The pooled hazard ratios (HRs) for overall and recurrence-free survival in patients with high CXCL12 expression were 1.39 (95% CI: 1.17-1.65, P=0.0002) and 1.12 (95% CI: 0.82-1.53, P=0.48) respectively, but with significant heterogeneity between studies. On subgroup analysis by cancer type, high CXCL12 expression was associated with reduced overall survival in patients with oesophagogastric (HR 2.08; 95% CI: 1.31-3.33, P=0.002), pancreatic (HR 1.54; 95% CI: 1.21-1.97, P=0.0005) and lung cancer (HR 1.37; 95% CI: 1.08-1.75, P=0.01), whereas in breast cancer patients high CXCL12 expression conferred an overall survival advantage (HR 0.5; 95% CI: 0.38-0.66, P<0.00001).

conclusionsDetermination of CXCL12 expression has the potential to be of use as a cancer biomarker and adds prognostic information in various cancer types. Prospective or prospective-retrospective analyses of CXCL12 expression in clearly defined cancer cohorts are now required to advance our understanding of the relationship between CXCL12 expression and cancer outcome.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBreast NeoplasmsChemokine CXCL12Colorectal NeoplasmsDisease-Free SurvivalEsophageal NeoplasmsFemaleHumansLung NeoplasmsMaleNeoplasmsPancreatic NeoplasmsPrognosisProstatic NeoplasmsStomach NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedChemokine CXCL12cixutumumabCXCL12 protein, human

Identifiers

PMID28535157
PMCPMC5520200
OpenAlexW2619167255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.